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Association Between Administration of Systemic Corticosteroids
and Mortality Among Critically Ill Patients With COVID-19
A Meta-analysis
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group
IMPORTANCE Effective therapies for patients with coronavirus disease 2019 (COVID-19) are
needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced
mortality in hospitalized patients with COVID-19 who required respiratory support.
OBJECTIVE To estimate the association between administration of corticosteroids compared
with usual care or placebo and 28-day all-cause mortality.
DESIGN, SETTING, AND PARTICIPANTS Prospective meta-analysis that pooled data from 7
randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill
patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to
June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated
from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed
using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was
assessed using the I2 statistic. The primary analysis was an inverse variance–weighted
fixed-effect meta-analysis of overall mortality, with the association between the intervention
and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were
conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp
adjustment) and an inverse variance–weighted fixed-effect analysis using risk ratios.
EXPOSURES Patients had been randomized to receive systemic dexamethasone,
hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo
(1025 patients).
MAIN OUTCOMES AND MEASURES The primary outcome measure was all-cause mortality
at 28 days after randomization. A secondary outcome was investigator-defined serious
adverse events.
RESULTS A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years];
488 [29%] women) were included in the analysis. Risk of bias was assessed as “low” for 6 of
the 7 mortality results and as “some concerns” in 1 trial because of the randomization method.
Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were
222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the
1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82];
P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the
trial results (I2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI,
0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary
OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for
dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527
deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients,
and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone
(1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events,
64 events occurred among 354 patients randomized to corticosteroids and 80 events
occurred among 342 patients randomized to usual care or placebo.
CONCLUSIONS AND RELEVANCE In this prospective meta-analysis of clinical trials of critically ill
patients with COVID-19, administration of systemic corticosteroids, compared with usual care
or placebo, was associated with lower 28-day all-cause mortality.
JAMA. doi:10.1001/jama.2020.17023
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T he role of corticosteroids in treating severe infectionshas been an enduring controversy.1-3 During the coro-navirus disease 2019 (COVID-19) pandemic, rigorous
data on the efficacy of corticosteroids have been limited.4,5 The
pandemic has been a potent stimulus for clinical research ad-
dressing this controversy.
As of July 24, 2020, 55 studies of corticosteroids for the treat-
ment of COVID-19 have been registered on ClinicalTrials.gov.
Recognizing the urgency of generating reliable data on the effi-
cacy of corticosteroids to guide clinical management, the Clini-
cal Characterization and Management Working Group of the
World Health Organization (WHO) developed a protocol for a pro-
spective meta-analysis6 of ongoing randomized clinical trials.
While this initiative was in development, the UK-based
Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial
reported its findings from 6425 patients randomized to 6 mg/d
of dexamethasone or usual care. Overall, dexamethasone re-
sulted in an absolute reduction in mortality of 2.8% (22.9% vs
25.7% for usual care; age-adjusted rate ratio, 0.83 [95% CI, 0.75-
0.93]). The benefit was greatest for patients who were receiv-
ing invasive mechanical ventilation at the time of randomiza-
tion with mortality of 29.3% for dexamethasone vs 41.4% for
usual care (rate ratio, 0.64 [95% CI, 0.51-0.81]).7 The signal seen
in this trial led most ongoing trials of corticosteroids to sus-
pend recruitment.
The objective of this prospective meta-analysis of ran-
domized trials was to estimate the association between ad-
ministration of corticosteroids, compared with usual care or
placebo, and 28-day all-cause mortality in hospitalized, criti-
cally ill patients with suspected or confirmed COVID-19.
Methods
Identification of Trials
Trials were identified through a comprehensive systematic
search of ClinicalTrials.gov, the Chinese Clinical Trial Regis-
try, and the EU Clinical Trials Register, from December 31,
2019, to April 6, 2020. All recruiting clinical trials related to
COVID-19 that examined the therapeutic efficacy of cortico-
steroids were identified.
The search terms used to identify studies for the meta-
analysis were COVID-19, corticosteroids, and steroids. Thirteen
clinical trials were identified using these search terms. Three
additional records not identified in the registries were identi-
fied through experts from the WHO Rapid Evidence Ap-
praisal for COVID-19 Therapies (REACT) Working Group. Three
staff members at the W2O Group conducted the initial search,
the results of which were presented to the protocol writing
group. The protocol writing group determined by consensus
whether trials met the inclusion criteria.
Development of Prospective Meta-analysis
Senior investigators of all trials identified as potentially eli-
gible were asked to participate in weekly calls starting on
May 14, 2020, during which plans for the prospective meta-
analysis and drafts of the protocol were developed and
reviewed. The protocol was registered and made publicly avail-
able on the PROSPERO database (CRD42020197242) on July
6, 2020, and has been published.8
Based on information from the published protocols and
prior communications with trial investigators, the trials that
had randomly assigned critically ill patients to a group in whom
corticosteroids were administered and to a group in whom cor-
ticosteroids were not administered were invited by the WHO
chief scientist on behalf of the Clinical Characterization and
Management Working Group of the WHO to participate in the
prospective meta-analysis. The protocol for the prospective
meta-analysis stipulated that no additional trials would be in-
cluded after outcome data were shared, but that if results from
further eligible trials became available before the results of the
prospective meta-analysis were published, additional meta-
analyses including these results would be conducted and re-
ported. Additional potentially eligible trials were identified
through contact with experts and when published in peer-
reviewed journals.
All trials secured institutional review board approval, but
approval was not required for the secondary data analysis re-
ported here. Informed consent for participation in each trial was
obtained and was consistent with local institutional review
board requirements. There were minor variations in the defi-
nitions of critically ill used to specify each trial’s eligibility cri-
teria (Table 1).9 The RECOVERY trial recruited both critically ill
and non–critically ill hospitalized patients. Because it was not
possible to distinguish whether patients had been critically ill
but not receiving invasive mechanical ventilation at the time of
randomization, data were requested only for the patients in the
RECOVERY trial who received invasive mechanical ventila-
tion. Data were pooled from patients recruited to the partici-
pating trials through June 9, 2020, because patient manage-
ment after that date was likely to be affected by the release of
results of the RECOVERY trial on June 16, 2020.
Outcomes
The primary outcome was all-cause mortality up to 30 days
after randomization and was determined before any out-
come data were available from any of the studies. Shorter-
term mortality (eg, 21 days) was acceptable if longer-term mor-
tality was not available. Five trials reported mortality at 28 days
after randomization; therefore, the primary outcome is re-
ported as 28-day all-cause mortality. The Community-
Acquired Pneumonia: Evaluation of Corticosteroids in
Key Points
Question Is administration of systemic corticosteroids associated
with reduced 28-day mortality in critically ill patients with
coronavirus disease 2019 (COVID-19)?
Findings In this prospective meta-analysis of 7 randomized trials
that included 1703 patients of whom 647 died, 28-day all-cause
mortality was lower among patients who received corticosteroids
compared with those who received usual care or placebo
(summary odds ratio, 0.66).
Meaning Administration of systemic corticosteroids, compared
with usual care or placebo, was associated with lower 28-day
all-cause mortality in critically ill patients with COVID-19.
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Coronavirus Disease (CAPE COVID; NCT02517489) trial10 re-
ported mortality at 21 days and the Glucocorticoid Therapy for
COVID-19 Critically Ill Patients With Severe Acute Respira-
tory Failure (Steroids-SARI; NCT04244591) trial reported mor-
tality at 30 days.
The secondary outcome was serious adverse events. De-
tails of the definitions and measurement of serious adverse
events were collected in advance of the trials sharing out-
come data.
Data Aggregation
Before sharing outcome data, trial investigators provided sum-
mary information on the characteristics of patients at the time
of randomization and the numbers of patients lost to follow-up
together with the age of each participant; these data were used
to calculate the median age across trials. Trial investigators then
provided summary tables showing the numbers of partici-
pants who did and did not experience each outcome accord-
ing to intervention group, overall, and in the following pa-
tient subgroups based on status at randomization: (1) whether
patients were receiving invasive mechanical ventilation,
(2) whether patients were receiving vasoactive medication,
(3) whether patients were aged 60 years or younger or were
older than 60 years (the median across trials), (4) sex (male or
female), and (5) whether patients had been symptomatic for
7 days or less or for more than 7 days. The fifth subgroup was
specified post hoc based on results from the RECOVERY trial.
All other subgroup analyses were prespecified before any out-
come data became available.
Risk of Bias Assessment
For each trial, we assessed the risk of bias (“low risk,” “some
concerns,” or “high risk” of bias) in the overall effect of corti-
costeroids on mortality and serious adverse events using ver-
sion 2 of the Cochrane Risk of Bias Assessment Tool.11 We also
assessed risk of bias for the effect of assignment to the inter-
vention. Risk of bias assessments were based on the trial pro-
tocols and flowcharts following the Consolidated Standards of
Reporting Trials together with this information supplied by the
investigators of each trial: (1) the methods used to generate the
allocation sequence and conceal randomized allocation;
(2) whether patients and health professionals were blinded to
assigned intervention; (3) the methods used to ensure that pa-
tients received their allocated intervention and the extent of
deviations from the assigned intervention; and (4) the meth-
ods used to measure mortality and serious adverse events. Risk
of bias assessments were done independently by 4 of the in-
vestigators (A.G., J.P.T.H., M.H.M., and J.S.), with disagree-
ments resolved through discussion. We used the Grading of
Recommendations Assessment, Development and Evalua-
tion (GRADE)12 approach to assess the certainty of the evi-
dence that corticosteroids reduce mortality in critically ill pa-
tients with COVID-19.
Data Analysis
We classified the trials according to the corticosteroid drug used
in the intervention group and whether the trial used a low dose
or a high dose of corticosteroids based on the following a priori–
defined cutoffs: 15 mg/d of dexamethasone, 400 mg/d of hy-
drocortisone, and 1 mg/kg/d of methylprednisolone.13 The pri-
mary analysis was an inverse variance–weighted fixed-effect
meta-analysis of odds ratios (ORs) for overall mortality, which
was repeated after excluding results from the RECOVERY trial.
We also conducted random-effects meta-analyses (with the
Paule-Mandel estimate of heterogeneity)14,15 and an inverse
variance–weighted fixed-effect analysis using risk ratios. We
applied the Hartung-Knapp adjustment16,17 to account for un-
certainty in the estimation of between-study variance in the
random-effects meta-analysis. This variance is imprecisely es-
timated when few studies are included and when some stud-
ies are small (both of which are the case with this meta-
analysis), leading to 95% CIs that are much wider than for the
fixed-effect analysis.
We quantified inconsistency in associations among the
trials using the I2 statistic and derived P values for heteroge-
neity using the Cochran Q statistic. We report precise P val-
ues. The protocol specified that a threshold for statistical sig-
nificance would not be used. Odds ratios with 95% CIs were
plotted for the association between corticosteroids, com-
pared with usual care or placebo, and serious adverse events.
Because the definitions of serious adverse events varied among
the trials, a meta-analysis of this outcome was not con-
ducted. Participants with missing outcome data were ex-
cluded from the analyses.
Evidence for differences in associations between the sub-
groups was quantified by ratios of ORs comparing associations
in the subgroups and the corresponding P values for interac-
tion. If the ratio of ORs is equal to 1, the estimated associations
in the 2 subgroups are the same. The further the ratio of ORs is
from 1, the greater is the difference between the estimated as-
sociations in the 2 subgroups. Comparisons between sub-
groups defined by trial characteristics were made using random-
effects meta-regression and interpreted as exploratory because
of the small number of trials and the potential for confounding
by other characteristics. Comparisons between subgroups de-
fined by patient characteristics were done by estimating the trial-
specific ratios of ORs comparing associations between sub-
groups and then combining these in meta-analyses.18
A hybrid approach was adopted for the analysis relating
to critically ill patients who were vs who were not receiving
invasive mechanical ventilation at randomization because in
some trials all patients were receiving invasive mechanical ven-
tilation. For this analysis, we compared the overall associa-
tions among critically ill patients who were and who were not
receiving invasive mechanical ventilation at randomization (in-
cluding patients in the RECOVERY trial who received inva-
sive mechanical ventilation) with the association among pa-
tients in the RECOVERY trial who required oxygen with or
without noninvasive ventilation but were not receiving inva-
sive mechanical ventilation at randomization.
To obtain illustrative estimates of absolute risks for the
overall analysis and for different types of corticosteroids, we
assumed a mortality risk without corticosteroids of 40%
(approximately, the risk among all patients allocated to usual
care or placebo) and applied the meta-analytic OR to obtain a
mortality risk with corticosteroids. To obtain illustrative
Research Original Investigation Association Between Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
E4 JAMA Published online September 2, 2020 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 09/02/2020
estimates of absolute risks for different patient subgroups, we
assumed a mortality risk equal to the observed risk across pa-
tients in that subgroup who were randomized to usual care or
placebo, and applied the subgroup meta-analytic OR to ob-
tain a mortality risk with corticosteroids in the subgroup.
Because the Randomized, Embedded, Multifactorial Adap-
tive Platform Trial for Community-Acquired Pneumonia
(REMAP-CAP; NCT02735707) trial19,20 assigned patients to both
high-dose and low-dose corticosteroid interventions, we
planned to use network meta-analysis to estimate associa-
tions between high-dose vs low-dose corticosteroids and mor-
tality. However, too few patients in this trial were randomized
to high-dose corticosteroids for such an analysis to be feasible.
All analyses were conducted using Stata statistical soft-
ware version 16 (StataCorp) and new Stata commands to con-
duct and graph the results of meta-analyses.
Results
Sixteen trials that were recruiting critically patients with
COVID-19 and had randomized patients to receive cortico-
steroids vs usual care or placebo were identified (Figure 1).
One trial (NCT04273321) did not respond to requests to
participate in the prospective meta-analysis and by May 2020
it had recruited 86 patients. Another trial (NCT04344730)
declined participation because randomization was ongoing
and by June 2020 it had recruited 14 patients. Other trials
were excluded because their investigators confirmed that
they had not recruited any patients (ChiCTR2000029656,
ChiCTR2000030481, and 2020-002191-12 [no longer
registered]), because they recruited patients with mild or
moderate disease (NCT04329650), or because randomization
did not include a group without corticosteroid treatment
(NCT04330586, 2020-001306-35, and NCT04251871).
Seven trials were included in the final meta-analysis
(Table 1). Patients were recruited from Australia, Brazil, Canada,
China, Denmark, France, Ireland, the Netherlands, New
Zealand, Spain, the UK, and the US. Patients were recruited
from February 26, 2020, to June 9, 2020, and the date of final
follow-up was July 6, 2020. The corticosteroid groups in-
cluded dexamethasone at low and high doses, low-dose hy-
drocortisone, and high-dose methylprednisolone. The Effi-
cacy of Dexamethasone Treatment for Patients With ARDS
Caused by COVID-19 (DEXA-COVID 19; NCT04325061) trial and
the COVID-19 Dexamethasone (CoDEX; NCT04327401) trial21
only enrolled patients receiving invasive mechanical ventila-
tion. For the RECOVERY trial,7 only patients who received in-
vasive mechanical ventilation at randomization were in-
cluded in the primary analysis. The REMAP-CAP trial19,20
(NCT02735707) and the Steroids-SARI (NCT04244591) trial
only enrolled patients admitted to an intensive care unit. The
CAPE COVID trial10 (NCT02517489) enrolled patients admitted
to an intensive care unit or an intermediate care unit who were
receiving a minimum of 6 L/min of supplemental oxygen. The
Hydrocortisone for COVID-19 and Severe Hypoxia (COVID
STEROID; NCT04348305) trial enrolled patients receiving a
minimum of 10 L/min of supplemental oxygen. The definitions
of serious adverse events varied between the trials, and mainly
focused on secondary infections and sepsis (Table 1).
A total of 1703 patients were randomized (678 to cortico-
steroids and 1025 to usual care or placebo) in the 7 trials, the
median age was 60 years (interquartile range, 52-68 years), and
488 patients (29%) were women (Table 2). The larger number
of patients randomized to usual care or placebo was due to ran-
domization in the RECOVERY trial (contributed 1007 [59.1%]
patients to this analysis) in which patients were assigned to cor-
ticosteroid or usual care in a ratio of 1:2. Most patients had se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection confirmed by polymerase chain reaction; and the pro-
portions of patients with SARS-CoV-2 infection confirmed by
polymerase chain reaction ranged from 78.7% to 100% across
trials. In all trials, the majority of patients were male. The ex-
tent of concurrent treatment with antiviral agents or azithro-
mycin varied substantially among the trials (Table 2).
There were minimal missing outcome data. Follow-up was
complete for both mortality and serious adverse events for 4
of the 7 trials. In the RECOVERY trial (NCT04381936), 1 patient
who received invasive mechanical ventilation (of 1007) in the
corticosteroid group withdrew consent. In the CAPE COVID trial
(NCT02517489), 1 patient (of 76) in the corticosteroid group
withdrew consent. In the REMAP-CAP trial (NCT02735707),
5 patients (of 110) withdrew consent in the corticosteroid group
and 6 patients (of 98) withdrew consent in the usual care group.
Association Between Corticosteroids
and 28-Day All-Cause Mortality
Risk of bias was assessed as “low” for 6 of the 7 mortality
results and as “some concerns” for the Steroids-SARI trial
(NCT04244591; eTable 1 in the Supplement) because this
trial used a fixed-randomization block size within centers and
used text messages to implement randomization allocations.
Figure 1. Flow Diagram Showing the Identification of Eligible Trials and
Participating Trials
16 Trials identified
13 Found via database searches
3 Found via other sources
16 Screened after duplicates removed
7 Excluded
3 Wrong interventions
3 Not yet recruiting
1 Ineligible population




1 Declined participation due to
ongoing recruiting for trial
9 Trial investigators contacted
for participation
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In the RECOVERY trial (NCT04381936), approximately 16%
of patients in the control group received dexamethasone. This
was regarded as reflecting usual practice,22 and was not
considered to introduce a risk of bias in the effect of assignment
to the intervention. Furthermore, any such bias would be
toward the null.
There were 222 deaths among 678 patients randomized to
corticosteroids and 425 deaths among 1025 patients random-
ized to usual care or placebo. Based on a fixed-effect meta-
analysis, the summary OR was 0.66 (95% CI, 0.53-0.82;
P < .001) for all-cause mortality comparing corticosteroids with
usual care or placebo (Figure 2). This corresponds to an abso-
lute mortality risk of 32% with corticosteroids compared with
an assumed mortality risk of 40% with usual care or placebo.
There was little inconsistency between the trial results
(I2 = 15.6%; P = .31 for heterogeneity), and the summary OR was
0.70 (95% CI, 0.48-1.01; P = .053) based on a random-effects
meta-analysis.
In the analysis that excluded patients recruited to the
RECOVERY trial, the OR was 0.77 (95% CI, 0.56-1.07) for all-
cause mortality comparing corticosteroids with usual care or
placebo, which was consistent with the corresponding result
based on patients in the RECOVERY trial who were receiving
invasive mechanical ventilation at randomization (OR, 0.59
[95% CI, 0.44-0.78]). This latter OR was not adjusted for age
and therefore differs from the age-adjusted rate ratio in the re-
port of the RECOVERY trial.7
The overall inverse variance–weighted fixed-effect risk ra-
tio was 0.80 (95% CI, 0.70-0.91) for all-cause mortality com-
paring corticosteroids with usual care or placebo. The GRADE
assessment of the certainty of the evidence that corticoste-
roids reduce all-cause mortality in critically ill patients with
COVID-19 was moderate due to minor concerns across (1) im-
precision, (2) a small amount of heterogeneity, and (3) a small
risk of reporting bias due to some trials not responding to the
requests for data.
For all-cause mortality comparing corticosteroids vs usual
care or placebo, the fixed-effect summary OR was 0.64 (95% CI,
0.50-0.82; P < .001) for trials of dexamethasone (3 trials, 1282
patients, and 527 deaths; corresponding absolute risk of 30%
for dexamethasone vs an assumed risk of 40% for usual care
or placebo) and the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for
trials of hydrocortisone (3 trials, 374 patients, and 94 deaths;
corresponding absolute risk of 32% for hydrocortisone vs an as-
sumed risk of 40% for usual care or placebo). Using meta-
regression to compare the associations for hydrocortisone and
dexamethasone, the ratio of ORs was 1.06 (95% CI, 0.37-2.99).
From the random-effects meta-analyses, the OR was 0.65 (95%
CI, 0.36-1.17) for dexamethasone and the OR was 0.87 (95% CI,
0.072-10.5) for hydrocortisone; the wide 95% CIs reflect the im-
precisely estimated between-trial variance because each analy-
sis included only 3 trials. Only 1 trial (NCT04244591), which
enrolled 47 patients of whom 26 died, evaluated
methylprednisolone and the OR was 0.91 (95% CI, 0.29, 2.87;








Odds ratio (95% CI)
No. of deaths/total




(95% CI)Steroids No steroids
100.0Overall (fixed effect)
P = .31 for heterogeneity; I2 = 15.6%
0.66 (0.53-0.82)222/678 425/1025
Overall (random effectsa) 0.70 (0.48-1.01)222/678 425/1025
76.60Subgroup fixed effect 0.64 (0.50-0.82)166/459 361/823
0.92High: 20 mg/d intravenously 2/7 2/12DEXA-COVID 19 NCT04325061 2.00 (0.21-18.69)
18.69High: 20 mg/d intravenously 69/128 76/128CoDEX NCT04327401 0.80 (0.49-1.31)
57.00Low: 6 mg/d orally or intravenously 95/324 283/683RECOVERY NCT04381936 0.59 (0.44-0.78)
Hydrocortisone
19.94Subgroup fixed effect 0.69 (0.43-1.12)43/195 51/179
6.80Low: 200 mg/d intravenously 11/75 20/73CAPE COVID NCT02517489 0.46 (0.20-1.04)
Methylprednisolone
3.46High: 40 mg every 12 h intravenously 13/24 13/23Steroids-SARI NCT04244591 0.91 (0.29-2.87)
1.39Low: 200 mg/d intravenously 6/15 2/14COVID STEROID NCT04348305 4.00 (0.65-24.66)
11.75Low: 50 mg every 6 h intravenously 26/105 29/92REMAP-CAP NCT02735707 0.71 (0.38-1.33)
ClinicalTrials.gov
identifier
The area of the data marker for each trial is proportional to its weight in the
fixed-effect meta-analysis. The Randomized Evaluation of COVID-19 Therapy
(RECOVERY) trial result is for patients who were receiving invasive mechanical
ventilation at randomization. CAPE COVID indicates Community-Acquired
Pneumonia: Evaluation of Corticosteroids in Coronavirus Disease; CoDEX,
COVID-19 Dexamethasone; COVID STEROID, Hydrocortisone for COVID-19 and
Severe Hypoxia; DEXA-COVID 19, Efficacy of Dexamethasone Treatment for
Patients With ARDS Caused by COVID-19; REMAP-CAP, Randomized,
Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired
Pneumonia; Steroids-SARI, Glucocorticoid Therapy for COVID-19 Critically Ill
Patients With Severe Acute Respiratory Failure.
a The random-effects analysis estimates both the average and variability of
effects across studies. The 95% CI for the average effect (shown here) is wide
because there is a small number of studies, some of which have very small
sample size. The prespecified primary analysis was the fixed-effect analysis,
which should be used to guide clinical interpretation of the results.
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P = .87) for the association between methylprednisolone and all-
cause mortality.
In trials that administered low doses of corticosteroids, the
overall fixed-effect OR was 0.61 (95% CI, 0.48-0.78; P < .001)
and the corresponding absolute risk was 29% for low-dose cor-
ticosteroids vs an assumed risk of 40% for usual care or pla-
cebo. In trials that administered high doses of corticoste-
roids, the fixed-effect OR was 0.83 (95% CI, 0.53-1.29; P = .46)
and the corresponding absolute risk was 36% for high-dose cor-
ticosteroids vs an assumed risk of 40% for usual care or pla-
cebo. The ratio of ORs was 1.38 (95% CI, 0.69-2.79; P = .29).
For trials that administered low-dose corticosteroids, the ran-
dom-effects OR was 0.80 (95% CI, 0.063-10.32; P = .75). For
trials that administered high-dose corticosteroids, the fixed-
effect and random-effects estimates were identical (I2 = 0%).
We identified 1 additional trial, the Methylprednisolone in
the Treatment of Patients With Signs of Severe Acute Respi-
ratory Syndrome in Covid-19 (Metcovid; NCT04343729),23
when it was published on August 12, 2020 (eTables 2 and 3 in
the Supplement); this trial had been registered after the
searches of trial registries had been conducted. In this trial, 416
hospitalized patients with suspected SARS-CoV-2 infection
were randomized to receive high-dose methylprednisolone or
placebo. The risk of bias in the effect of assignment to inter-
vention on 28-day mortality was assessed as “low” (eTable 4
in the Supplement). In an additional meta-analysis that in-
cluded patients (71 in the steroid group and 70 in the no ste-
roid group) from the Metcovid trial who were receiving inva-
sive mechanical ventilation at randomization (based on an
intention-to-treat analysis), the fixed-effect OR was 0.66 (95%
CI, 0.54-0.82; P < .001) for the association between cortico-
steroids and 28-day mortality (eFigure 6 in the Supplement).
There was little inconsistency among the trials (random-
effects OR, 0.67 [95% CI, 0.51-0.87]; P = .009 and I2 = 2.4%).
For the association between methylprednisolone and 28-day
mortality, the fixed-effect OR was 0.80 (95% CI, 0.40-1.63;
P = .54).
Association Between Corticosteroids and 28-Day All-Cause
Mortality Within Subgroups
The estimated associations between corticosteroids vs usual
care or placebo and mortality in the subgroups defined by pa-
tient characteristics at randomization appear in Figure 3.
Among critically ill patients, many more were receiving inva-
sive mechanical ventilation at randomization (1459 patients
and 604 deaths) than were not (144 patients and 42 deaths).
The overall fixed-effect OR was 0.69 (95% CI, 0.55-0.86) among
patients who were receiving invasive mechanical ventilation
at randomization (corresponding to an absolute risk of 30% for
corticosteroids vs 38% for usual care or placebo) and the OR
was 0.41 (95% CI, 0.19-0.88) among patients who were not re-
ceiving invasive mechanical ventilation at randomization (cor-
responding to an absolute risk of 23% for corticosteroids vs 42%
for usual care or placebo). For comparison, the OR was 0.86
(95% CI, 0.73-1.00) among 3883 patients in the RECOVERY trial
who required oxygen with or without noninvasive ventila-
tion but were not receiving invasive mechanical ventilation at
randomization.7
Among the 4 trials that recruited critically ill patients who
were and were not receiving invasive mechanical ventilation
at randomization, the association between corticosteroids and
lower mortality was less marked in patients receiving inva-
sive mechanical ventilation (ratio of ORs, 4.34 [95% CI, 1.46-
12.91]; P = .008 based on within-trial estimates combined
Figure 3. Association Between Corticosteroids and 28-Day All-Cause Mortality Within Subgroups Defined













(95% CI)Steroids No steroids
Invasive mechanical ventilation (IMV)
2.714/70 28/74No (I2 = 0%) 0.41 (0.19-0.88)
31.7208/608 397/951Yes (I2 = 44.1%) 0.69 (0.55-0.86)




50.251/184 68/184No (I2 = 0%) 0.55 (0.34-0.88)
49.876/169 74/158Yes (I2 = 0%) 1.05 (0.65-1.69)
Age, y
42.772/338 141/483≤60 (I2 = 0%) 0.67 (0.48-0.94)
57.3150/339 284/541>60 (I2 = 49.7%) 0.69 (0.51-0.93)
Sex
27.460/202 106/286Female (I2 = 0%) 0.66 (0.43-0.99)
72.6162/476 319/739Male (I2 = 14.7%) 0.66 (0.51-0.84)
Symptomatic, d
22.451/130 99/211≤7 (I2 = 69.1%) 0.63 (0.39-1.04)
77.6139/418 293/693>7  (I2 = 0%) 0.64 (0.49-0.83)
The area of the data markers is
proportional to their weight in the
meta-analysis. The estimated odds
ratios were derived using fixed-effect
meta-analyses across all trials for
which data on the specified subgroup
were available. The results for
patients in the Randomized
Evaluation of COVID-19 Therapy
(RECOVERY) trial who required
oxygen with or without noninvasive
ventilation but were not receiving
invasive mechanical ventilation at
randomization is shown in a light blue
box because these data were not
otherwise included in this
prospective meta-analysis.
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across trials; eFigure 1 in the Supplement); however, only 401
patients (120 deaths) contributed to this comparison.
Among 695 patients from 6 trials for whom data were avail-
able, 327 (47.0%) were receiving vasoactive agents for blood
pressure support at randomization. For the association be-
tween corticosteroids and mortality, the OR was 1.05 (95% CI,
0.65-1.69) among patients who were receiving vasoactive
agents at randomization (an absolute risk of 48% for cortico-
steroids vs 47% for usual care or placebo) and the OR was 0.55
(95% CI, 0.34-0.88) among patients who were not receiving
vasoactive agents at randomization (an absolute risk of 24%
for corticosteroids vs 37% for usual care or placebo). The ratio
of ORs was 1.90 (95% CI, 0.97-3.73, P = .06; eFigure 2 in the
Supplement).
All trials contributed data according to age group and sex.
For the association between corticosteroids and mortality,
the OR was 0.69 (95% CI, 0.51-0.93) among 880 patients
older than 60 years, the OR was 0.67 (95% CI, 0.48-0.94)
among 821 patients aged 60 years or younger (ratio of ORs,
1.02 [95% CI, 0.63-1.65], P = .94; eFigure 3 in the Supple-
ment), the OR was 0.66 (95% CI, 0.51-0.84) among 1215 men,
and the OR was 0.66 (95% CI, 0.43-0.99) among 488 women
(ratio of ORs, 1.07 [95% CI, 0.58-1.98], P = .84; eFigure 4 in
the Supplement). For the association between corticosteroids
and mortality based on data from 4 trials, the OR was 0.64
(95% CI, 0.49-0.83) among 1111 patients who were sympto-
matic for more than 7 days prior to randomization and the OR
was 0.63 (95% CI, 0.39-1.04) among 341 patients who were
symptomatic for 7 days or less prior to randomization (ratio
of ORs, 1.07 [95% CI, 0.40-2.81], P = .90; eFigure 5 in the
Supplement).
Serious Adverse Events
The RECOVERY trial did not record serious adverse events.
The Steroids-SARI trial (NCT04244591) recorded adverse
events but did not categorize them as serious or nonserious
adverse events. Risk of bias was assessed as “low” in 2 of the
6 available trial results for serious adverse events (eTable 1 in
the Supplement). In these trials, the study personnel were
blinded to the intervention group. The other 4 trials had
unblinded outcome assessment, and the risk of bias was
assessed as “some concerns” based on subjectivity implying
that classification of serious adverse events could differ
between intervention groups.
The associations between corticosteroids vs usual care or
placebo and serious adverse events in each trial appear in
Figure 4. Among the 6 trials that reported serious adverse
events, 64 events occurred among 354 patients randomized
to corticosteroids and 80 events occurred among 342 pa-
tients randomized to usual care or placebo. Adverse events var-
ied across trials but there was no suggestion that the risk of
serious adverse events was higher in patients assigned to cor-
ticosteroids except for the 2 smallest trials, in which the total
number of serious adverse events was 1 and 3.
Discussion
In this prospective meta-analysis of 7 randomized clinical trials
that included 1703 critically ill patients with COVID-19 re-
cruited from countries on 5 continents, administration of cor-
ticosteroids was associated with lower all-cause mortality at
28 days after randomization. There was no suggestion of an
increased risk of serious of adverse events. The ORs for the as-
sociation between corticosteroids and mortality were similar
for dexamethasone and hydrocortisone. The comparison of the
association between low-dose corticosteroids and mortality
and the association between high-dose corticosteroids and
mortality was imprecisely estimated.
Corticosteroids were associated with lower mortality
among critically ill patients who were and were not receiving
invasive mechanical ventilation at randomization, as well as










(95% CI)Steroids No steroids
High: 20 mg/d intravenously 3/7 11/12DEXA-COVID 19 NCT04325061 0.07 (0.01-0.86)
High: 20 mg/d intravenously 7/128 15/128CoDEX NCT04327401 0.44 (0.17-1.11)
Hydrocortisone
Low: 200 mg/d intravenously 28/75 30/73CAPE COVID NCT02517489 0.85 (0.44-1.65)
Methylprednisolone
High: 40 mg every 12 h intravenously 23/24 23/23Steroids-SARI NCT04244591 0.33 (0.01-8.61)
Low: 200 mg/d intravenously 1/15 0/14COVID STEROID NCT04348305 3.00 (0.11-79.91)




Odds ratio (95% CI)
The area of the data markers is proportional to the inverse of the variance of the
estimated odds ratio. CAPE COVID indicates Community-Acquired Pneumonia:
Evaluation of Corticosteroids in Coronavirus Disease; CoDEX, COVID-19
Dexamethasone; COVID STEROID, Hydrocortisone for COVID-19 and Severe
Hypoxia; DEXA-COVID 19, Efficacy of Dexamethasone Treatment for Patients
With ARDS Caused by COVID-19; REMAP-CAP, Randomized, Embedded,
Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia;
Steroids-SARI, Glucocorticoid Therapy for COVID-19 Critically Ill Patients With
Severe Acute Respiratory Failure. The Steroids-SARI trial recorded adverse
events but did not categorize them as serious or nonserious.
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in patients from the RECOVERY trial who required oxygen with
or without noninvasive ventilation but were not receiving in-
vasive mechanical ventilation at randomization. These re-
sults were consistent with the subgroup analysis suggesting
that the association between corticosteroids and lower mor-
tality was stronger in patients who were not receiving vaso-
active medication at randomization than in those who were
receiving vasoactive medication at randomization. The ORs for
the association between corticosteroids and mortality ap-
peared similar for older and younger individuals, men and
women, and for longer and shorter durations of symptoms be-
fore randomization.
This analysis was expedited because of the release of
results from the RECOVERY trial, which found that the abso-
lute risk of death was reduced by 12.1% among those assigned
to low-dose dexamethasone who were receiving invasive
mechanical ventilation at randomization. Most ongoing trials
of corticosteroids in critically ill patients with COVID-19
suspended enrollment after these results became publicly
available because equipoise for withholding corticosteroids
was no longer present. These trial results from diverse clini-
cal and geographic settings suggest that in the absence of
compelling contraindications, a corticosteroid regimen
should be a component of standard care for critically ill
patients with COVID-19.
The optimal dose and duration of treatment could not be
assessed in this analysis, but there was no evidence suggest-
ing that a higher dose of corticosteroids was associated with
greater benefit than a lower dose of corticosteroids. Inclusion
of data from the Metcovid trial did not materially change the
results other than reducing the inconsistency among the trials.
Data from the Metcovid trial were not included in the pri-
mary meta-analysis because this trial was registered after the
searches of the trial registries were conducted.
All subgroup analyses other than that comparing longer
with shorter duration of symptoms at randomization were pre-
specified. Although the benefit associated with corticoste-
roids appeared greater in critically ill patients who were not
receiving invasive mechanical ventilation at randomization,
this comparison was based on only 4 trials and 144 patients
who were not receiving invasive mechanical ventilation at ran-
domization, of whom 42 died. Corticosteroids were associ-
ated with lower mortality in critically ill patients who were and
were not receiving invasive mechanical ventilation at random-
ization, as well as in patients in the RECOVERY trial who re-
quired oxygen with or without noninvasive ventilation but
were not receiving invasive mechanical ventilation at
randomization.7 It was not possible to classify this latter group
according to whether they were critically ill at the time of ran-
domization. These patients represented a spectrum of illness
from patients receiving supplemental oxygen by nasal prongs
to those receiving noninvasive ventilatory support in the form
of high-flow oxygen or positive pressure by mask. Nonethe-
less, the substantial risk of death in these patients (682/2604
[26.1%] in the control group) is consistent with mortality in criti-
cally ill patients with COVID-19.24,25
The findings from this prospective meta-analysis provide
evidence that treatment with corticosteroids is associated
with reduced mortality for critically ill patients with COVID-
19. The findings contrast with outcomes reported for the
administration of corticosteroids among patients with influ-
enza, for whom mortality and hospital-acquired infections
may be increased by the administration of corticosteroids.26
In the current study, potential corticosteroid–induced com-
plications could not be analyzed reliably because of limita-
tions of the available data (serious adverse events were
reported by only 6 of the 7 trials, and their definitions and
methods of assessment varied among trials). However, seri-
ous adverse events were generally less likely in patients ran-
domized to corticosteroids than to usual care or placebo.
This prospective meta-analysis was based on a relatively
large number of critically ill patients with COVID-19 from
geographically diverse sites who were randomized to receive
corticosteroids or to receive usual care or placebo. The proto-
col and analysis plan, including specification of subgroup
analyses, was registered and made publicly available on the
PROSPERO database prior to data analysis or receipt of out-
come data. The protocol also has been published along with a
structured abstract.8 Provision of pooled data in prespecified
subgroups facilitated rapid analysis and dissemination
because a need for multiple data-sharing agreements was
avoided. As is standard in meta-analyses, patients were com-
pared only with other patients randomized in the same trial.
Therefore, observed associations support a causal relation-
ship between the administration of corticosteroids, com-
pared with usual care or placebo, and reduced mortality.
Limitations
This study has several limitations. First, the prospective na-
ture of this meta-analysis implies that there is little risk of se-
lective reporting or of publication bias,6 but it is possible that
lack of participation by some investigators of ongoing trials was
based on their knowledge of their trial results. Nonetheless,
the number of patients randomized in eligible trials who did
not participate is likely to be smaller than the number of pa-
tients included in this meta-analysis.
Second, all but 1 of the included trials was assessed as “low
risk” of bias for the effect of assignment to the intervention.
The trial for which the risk of bias was assessed as “some con-
cerns” (Steroids-SARI; NCT04244591) was relatively small (47
patients and 26 deaths) and contributed only 3.5% of the weight
in the primary meta-analysis. It was the only trial that as-
sessed the effect of methylprednisolone.
Third, there were only limited missing outcome data, but
in many trials, follow-up was censored when participants were
discharged from the hospital. We are aware of no reason that
the effect of corticosteroids on postdischarge 28-day mortal-
ity would differ from that on predischarge mortality, but it will
be important to report on longer-term mortality, including post-
discharge mortality, in future analyses.
Fourth, the definitions and reporting of serious adverse
events were not consistent across the trials and therefore a meta-
analysis for this secondary end point was not conducted.
Fifth, the trials only recruited adults, and the effect of cor-
ticosteroids on children remains unclear. Similarly, the trials
were mainly conducted in high-income settings.
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Sixth, 1 trial reported mortality at 21 days and 1 trial re-
ported mortality at 30 days after randomization, potentially
leading to inconsistency between trial results.
Seventh, the RECOVERY trial contributed 57% of the weight
in the primary meta-analysis of 28-day all-cause mortality, al-
though there was little inconsistency between the effects of cor-
ticosteroids on 28-day mortality estimated by the different trials.
Conclusions
In this prospective meta-analysis of clinical trials of critically
ill patients with COVID-19, administration of systemic corti-
costeroids, compared with usual care or placebo, was associ-
ated with lower 28-day all-cause mortality.
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